Journal of Pharmacy and Pharmacology · 2006 · 72 citations · 54 references
MedicineBiochemistryPharmacologyCancer PharmacologyDrug DiscoveryWine ChemistryFlavonoid BiosynthesisWine Composition AnalysisAntioxidant MetabolitesAntioxidant PropertiesGlucuronidation PathwaysHepatic Drug-drug InteractionsHuman Intestinal MicrosomesIntestinal Drug-drug InteractionsIntestinal Ugt-mediated Glucuronidation
Resveratrol (trans-resveratrol, trans-3,5,4'-trihydroxystilbene) is a naturally occurring stilbene analogue found in high concentrations in red wine. There is considerable research interest to determine the therapeutic potential of resveratrol, as it has been shown to have tumour inhibitory and antioxidant properties. This study was performed to investigate the glucuronidation of resveratrol and possible drug interactions via glucuronidation. Two glucuronide conjugates, resveratrol 3-O-glucuronide and resveratrol 4'-O-glucuronide, were formed by human liver and intestinal microsomes. UGT1A1 and UGT1A9 were predominantly responsible for the formation of the 3-O-glucuronide (Km = 149 microM) and 4'-O-glucuronide (Km = 365 microM), respectively. The glucuronide conjugates were formed at higher levels (up to 10-fold) by intestinal rather than liver microsomes. Resveratrol was co-incubated with substrates of UGT1A1 (bilirubin and 7-ethyl-10-hydroxycamptothecin (SN-38)) and UGT1A9 (7-hydroxytrifluoromethyl coumarin (7-HFC)). No major changes were noted in bilirubin glucuronidation in the presence of resveratrol. Resveratrol significantly inhibited the glucuronidation of SN-38 (Ki = 6.2 +/- 2.1 microM) and 7-HFC (Ki = 0.6 +/- 0.2 microM). Hence, resveratrol has the potential to inhibit the glucuronidation of concomitantly administered therapeutic drugs or dietary components that are substrates of UGT1A1 and UGT1A9.
54
HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Thomas Walle, Faye Hsieh, Mark H. DeLegge et al. · Drug Metabolism and Disposition · 2004 · 1.8K citations
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Bharat B. Aggarwal, Anjana Bhardwaj, Rishi S. Aggarwal et al. · PubMed · 2004 · 1.4K citations
Medicine, Oncology, Pharmacology +13
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Lalitha Iyer, Soma Das, Linda Janisch et al. · The Pharmacogenomics Journal · 2002 · 712 citations